• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations.利用溶剂暴露的盐桥相互作用,通过自由能微扰模拟发现SOS1的强效抑制剂。
ACS Med Chem Lett. 2025 Feb 28;16(3):444-453. doi: 10.1021/acsmedchemlett.4c00602. eCollection 2025 Mar 13.
2
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
3
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
6
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
7
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.液体活检能否通过低深度全基因组测序检测肉瘤患者的循环肿瘤DNA?一项初步评估。
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
8
A New Measure of Quantified Social Health Is Associated With Levels of Discomfort, Capability, and Mental and General Health Among Patients Seeking Musculoskeletal Specialty Care.一种新的量化社会健康指标与寻求肌肉骨骼专科护理的患者的不适程度、能力以及心理和总体健康水平相关。
Clin Orthop Relat Res. 2025 Apr 1;483(4):647-663. doi: 10.1097/CORR.0000000000003394. Epub 2025 Feb 5.
9
"In a State of Flow": A Qualitative Examination of Autistic Adults' Phenomenological Experiences of Task Immersion.“心流状态”:对自闭症成年人任务沉浸现象学体验的质性研究
Autism Adulthood. 2024 Sep 16;6(3):362-373. doi: 10.1089/aut.2023.0032. eCollection 2024 Sep.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.

本文引用的文献

1
Lead Identification of Novel Naphthyridine Derivatives as Potent SOS1 Inhibitors.新型萘啶衍生物作为强效SOS1抑制剂的先导化合物鉴定
ACS Med Chem Lett. 2024 Jun 3;15(6):958-964. doi: 10.1021/acsmedchemlett.4c00156. eCollection 2024 Jun 13.
2
Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer.发现强效的七肽连接酶 1(SOS1)和表皮生长因子受体(EGFR)双重抑制剂,可用于治疗前列腺癌。
J Med Chem. 2024 May 9;67(9):7130-7145. doi: 10.1021/acs.jmedchem.3c02433. Epub 2024 Apr 17.
3
Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity.利用高能水合位点发现具有细胞抗病毒活性的 SARS-CoV-2 主蛋白酶强效肽醛抑制剂。
Bioorg Med Chem. 2024 Apr 1;103:117577. doi: 10.1016/j.bmc.2023.117577. Epub 2024 Jan 5.
4
Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS-driven lung adenocarcinoma.SOS1 对于 KRAS 驱动的肺腺癌肿瘤发生和微环境调节的关键要求。
Nat Commun. 2023 Sep 20;14(1):5856. doi: 10.1038/s41467-023-41583-1.
5
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.直接靶向 K-Ras 的抑制剂治疗癌症:进展、新见解和克服耐药策略。
Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:231-253. doi: 10.1146/annurev-pharmtox-022823-113946. Epub 2023 Jul 31.
6
Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.设计具有高选择性的口服生物利用度四环邻苯二甲酰亚胺 SOS1 抑制剂,针对 EGFR。
Bioorg Chem. 2023 Jul;136:106536. doi: 10.1016/j.bioorg.2023.106536. Epub 2023 Apr 10.
7
Design, Synthesis, and Bioevaluation of Pyrido[2,3-]pyrimidin-7-ones as Potent SOS1 Inhibitors.作为强效SOS1抑制剂的吡啶并[2,3 - ]嘧啶 - 7 - 酮的设计、合成及生物学评价
ACS Med Chem Lett. 2023 Jan 12;14(2):183-190. doi: 10.1021/acsmedchemlett.2c00490. eCollection 2023 Feb 9.
8
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.发现口服生物利用度 SOS1 抑制剂,用于抑制 KRAS 驱动的癌。
J Med Chem. 2022 Oct 13;65(19):13158-13171. doi: 10.1021/acs.jmedchem.2c00986. Epub 2022 Sep 29.
9
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.MRTX0902 的设计与发现:一种强效、选择性、可穿透血脑屏障、口服生物利用度的 SOS1:KRAS 蛋白-蛋白相互作用抑制剂。
J Med Chem. 2022 Jul 28;65(14):9678-9690. doi: 10.1021/acs.jmedchem.2c00741. Epub 2022 Jul 14.
10
Discovery of a Novel Class of d-Amino Acid Oxidase Inhibitors Using the Schrödinger Computational Platform.利用薛定谔计算平台发现一类新型的D-氨基酸氧化酶抑制剂
J Med Chem. 2022 May 12;65(9):6775-6802. doi: 10.1021/acs.jmedchem.2c00118. Epub 2022 Apr 28.

利用溶剂暴露的盐桥相互作用,通过自由能微扰模拟发现SOS1的强效抑制剂。

Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations.

作者信息

Leffler Abba E, Houang Evelyne M, Gray Felicia, Placzek Andrew T, Ruvinsky Anatoly M, Bell Jeffrey A, Wang Hui, Sun Shaoxian, Svensson Mats, Greenwood Jeremy R, Frye Leah L, Igawa Hideyuki, Atsriku Christian, Levinson Adam M

机构信息

Schrödinger, Inc., New York, New York 10036, United States.

Schrödinger, Inc., Portland, Oregon 97204, United States.

出版信息

ACS Med Chem Lett. 2025 Feb 28;16(3):444-453. doi: 10.1021/acsmedchemlett.4c00602. eCollection 2025 Mar 13.

DOI:10.1021/acsmedchemlett.4c00602
PMID:40104782
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11912288/
Abstract

Small molecules that bind the Son of Sevenless 1 protein (SOS1), thereby preventing activation of RAS, have been widely pursued as a means for cell proliferation inhibition and antitumor activity. Guided by free-energy perturbation (FEP+) simulations, we discovered that two acidic residues on the perimeter of a known small molecule binding site on SOS1, E906 and E909, constitute a potency handle that can improve inhibitor affinity by as much as 750-fold when targeted with basic groups to form salt bridges, despite being solvent exposed. Structure-Activity Relationship (SAR) and X-ray crystallographic studies demonstrate that this effect is attributable to the electrostatic interaction between the protein and ligand. This interaction could be repurposed to create new SOS1 inhibitors, documenting its general utility for core exploration. Additional recent examples in the literature suggest that this phenomenon may be applicable to a number of target classes and are highlighted herein.

摘要

与七号less之子1蛋白(SOS1)结合从而阻止RAS激活的小分子,已被广泛研究作为抑制细胞增殖和抗肿瘤活性的一种手段。在自由能微扰(FEP+)模拟的指导下,我们发现SOS1上一个已知小分子结合位点周边的两个酸性残基E906和E909,构成了一个效能调控位点,当用碱性基团靶向形成盐桥时,尽管它们暴露于溶剂中,但可将抑制剂亲和力提高多达750倍。构效关系(SAR)和X射线晶体学研究表明,这种效应归因于蛋白质与配体之间的静电相互作用。这种相互作用可被重新利用来创建新的SOS1抑制剂,证明了其在核心探索中的普遍效用。文献中最近的其他例子表明,这种现象可能适用于许多靶点类别,并在此予以强调。